Farxiga vs Januvia
Side-by-side cost comparison based on Medicare Part D data
Farxiga
Dapagliflozin
Manufactured by AstraZeneca
Januvia
Sitagliptin
Manufactured by Merck
Januvia costs 18% less per claim than Farxiga ($219.00 vs $266.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Farxiga | Januvia |
|---|---|---|
| Avg Cost Per Claim | $266.00 | $219.00 |
| Total Medicare Spending | $3.0B | $2.7B |
| Total Beneficiaries | 1,340,000 | 1,560,000 |
| Total Claims | 11,240,000 | 12,480,000 |
| Annual Cost/Patient | $2,229.00 | $1,753.00 |
| Year-over-Year Change | +31.5% | -12.3% |
| Generic Available | Yes | No |
| Patent Expiration | Nov 13, 2025 | Jul 17, 2026 |
| Manufacturer | AstraZeneca | Merck |
| Condition | Diabetes | Diabetes |
| Generic Name | Dapagliflozin | Sitagliptin |
Farxiga vs Januvia: What the Data Shows
Farxiga (Dapagliflozin) and Januvia (Sitagliptin) are both used to treat diabetes. Based on Medicare Part D data, Januvia costs $219.00 per claim, which is 18% less than Farxiga at $266.00 per claim.
Medicare spent $3.0B on Farxiga and $2.7B on Januvia. In terms of patient reach, Januvia serves more beneficiaries (1,560,000 vs 1,340,000).
Year-over-year spending changed +31.5% for Farxiga and -12.3% for Januvia. Farxiga saw significant spending growth, suggesting increased utilization or price increases.
Farxiga has a generic available, while Januvia remains brand-only until its patent expires Jul 17, 2026.
Frequently Asked Questions
Januvia is cheaper at $219.00 per claim, compared to $266.00 for Farxiga. That makes Januvia about 18% less expensive per claim based on Medicare Part D data.
Yes, both Farxiga and Januvia are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Farxiga has a generic version (Dapagliflozin) available, which is typically much cheaper. Januvia is currently brand-only, with patent expiring Jul 17, 2026.
Medicare Part D spent $3.0B on Farxiga covering 1,340,000 beneficiaries, and $2.7B on Januvia covering 1,560,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.